Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. doi: 10.1073/pnas.1006614107. Epub 2010 Oct 18.

2.

Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L.

Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.

3.

Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, Corey L.

J Virol. 2014 May;88(9):4921-31. doi: 10.1128/JVI.03285-13. Epub 2014 Feb 19.

4.

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A.

JAMA. 2011 Apr 13;305(14):1441-9. doi: 10.1001/jama.2011.420.

5.

Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.

Schiffer JT, Magaret A, Selke S, Corey L, Wald A.

J Antimicrob Chemother. 2011 Nov;66(11):2593-600. doi: 10.1093/jac/dkr346. Epub 2011 Aug 24.

6.

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Schiffer JT, Swan DA, Corey L, Wald A.

Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9. doi: 10.1128/AAC.01114-13. Epub 2013 Sep 9.

7.

The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Schiffer JT, Wald A, Selke S, Corey L, Magaret A.

J Infect Dis. 2011 Aug 15;204(4):554-61. doi: 10.1093/infdis/jir314.

8.

Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Schiffer JT, Corey L.

Nat Med. 2013 Mar;19(3):280-90. doi: 10.1038/nm.3103.

9.

Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.

Dhankani V, Kutz JN, Schiffer JT.

PLoS Comput Biol. 2014 Nov 6;10(11):e1003922. doi: 10.1371/journal.pcbi.1003922. eCollection 2014 Nov.

10.

Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L.

N Engl J Med. 2000 Mar 23;342(12):844-50.

11.

Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.

Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L.

J Exp Med. 2007 Mar 19;204(3):595-603. Epub 2007 Feb 26.

12.

Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.

Moss NJ, Magaret A, Laing KJ, Kask AS, Wang M, Mark KE, Schiffer JT, Wald A, Koelle DM.

J Virol. 2012 Sep;86(18):9952-63. doi: 10.1128/JVI.00829-12. Epub 2012 Jul 3.

13.

A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, BenMohamed L.

Mucosal Immunol. 2009 Mar;2(2):129-43. doi: 10.1038/mi.2008.81. Epub 2008 Dec 24.

14.

Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.

Zhang X, Dervillez X, Chentoufi AA, Badakhshan T, Bettahi I, Benmohamed L.

J Immunol. 2012 Nov 1;189(9):4496-509. doi: 10.4049/jimmunol.1201121. Epub 2012 Sep 26.

15.

Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.

Tata S, Johnston C, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Infect Dis. 2010 Feb 15;201(4):499-504. doi: 10.1086/650302.

16.

Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract.

Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R.

AIDS. 2007 Mar 12;21(5):589-98.

PMID:
17314521
17.

Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.

Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L.

J Infect Dis. 2008 Oct 15;198(8):1141-9. doi: 10.1086/591913.

18.

Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, Wald A, Corey L.

Sci Transl Med. 2009 Nov 18;1(7):7ra16. doi: 10.1126/scitranslmed.3000193.

20.

Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.

Leone P, Warren T, Hamed K, Fife K, Wald A.

Sex Transm Dis. 2007 Nov;34(11):900-7.

PMID:
17538513
Items per page

Supplemental Content

Write to the Help Desk